Home › Recently closed › 2026-07629
Establishing Impurity Specifications for Antibiotics; Draft Guidance for Industry; Availability
Read on FederalRegister.gov · Official PDF · Docket on Regulations.gov · Add to calendar (.ics)
Summary (from the Federal Register abstract)
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a draft guidance for industry entitled "Establishing Impurity Specifications for Antibiotics." The draft guidance provides recommendations regarding the establishment of specifications for organic impurities in antibiotics manufactured by fermentation and semi-synthesis. This draft guidance applies to antibiotic drugs subject to approval under new drug applications (NDAs) and abbreviated new drug applications (ANDAs) and associated type II drug substance drug master files (DMFs) referenced in antibiotic NDAs and ANDAs. This guidance also applies to nonprescription antibiotic drugs, often referred to as over-the-counter (OTC) monograph drugs. By providing these recommendations, FDA intends to clarify effective control strategies, support the development of high-quality antibiotic products, and promote consistency in quality standards.
- Document type
- Notice
- Federal Register document number
- 2026-07629
- Published
- Apr 20, 2026
- Action
- Notice of availability.
- Docket
- FDA-2025-D-6130
- Comments posted on Regulations.gov (at last check)
- 0
- DATES section (from the document)
- Submit either electronic or written comments on the draft guidance by June 22, 2026. to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.
- Topics (auto-tagged)
- CMC (chemistry, manufacturing & controls)
Source: Federal Register API, document 2026-07629. Federal Register text is a U.S. government work. Confirm dates in the official document; later documents may extend, reopen or correct them.